Sebela Pharmaceuticals:
Leading the Way

Sebela Pharmaceuticals Announces U.S. Launch of SUTAB® Tablets, An Alternative to Liquid Colonoscopy Preparation

Sebela Pharmaceuticals is uniquely positioned for significant growth organically and through acquisitions, in-licensing and partnerships. We offer market-leading treatments in gastroenterology, colorectal cancer prevention, dermatology and women’s health, including:

SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) Tablets, a sulfate-based tablet preparation for colonoscopy

IMPORTANT SAFETY INFORMATION SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. DOSAGE AND ADMINSTRATION: A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration. ADVERSE REACTIONS: Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting and upper abdominal pain. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance.

See Full Prescribing Information and Medication Guide

SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution, the #1 prescribed branded bowel prep kit1

IMPORTANT SAFETY INFORMATION SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 12 years of age and older. DOSAGE AND ADMINISTRATION: Each bottle must be diluted with water to a final volume of 16 ounces (Adults) and 12 ounces (Pediatric patients 12 years of age and older). Must consume additional water after each dose. Stop consumption of all fluids at least 2 hours prior to the colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal (GI) obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredients in SUPREP Bowel Prep Kit. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking medications that affect renal functions: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration. ADVERSE REACTIONS: Most common adverse reactions: Adults: (> 2%) are overall discomfort, abdominal distention, abdominal pain, nausea, and vomiting; Pediatric Patients (>10%) are nausea, abdominal pain, abdominal bloating and vomiting. DRUG INTERACTIONS: Drugs that may increase the risk of fluid and electrolyte abnormalities.

Click here for Full Prescribing Information and Medication Guide

NAFTIN® GEL 2% (Naftifine HCl), the #1 prescribed brand for interdigital tinea pedis1

INDICATIONS AND USAGE: NAFTIN (Naftifine HCl) GEL 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.

Please click here for full Prescribing Information about NAFTIN GEL 2%.

Our Products

Sebela Pharmaceuticals is dedicated to providing innovative prescription products to meet patients’ medical needs in gastroenterology, colorectal cancer prevention, dermatology and women’s health.

Professional Resources

Sebela Pharmaceuticals provides resources to healthcare providers including product samples, patient savings cards and patient educational materials. To find a local Sebela Pharmaceuticals sales representative or to request support materials, please call the Sebela Pharmaceuticals Promotional Support line at 1-888-246-1207 or click below.

Sebela Pharmaceuticals’ Commitment

Sebela Pharmaceuticals is committed to improving patients’ lives by developing, marketing, and selling differentiated brands of prescription pharmaceuticals for patients whose needs are not adequately satisfied. Sebela Pharmaceuticals’ commercial activities are focused on niche therapeutic markets in the United States, including gastroenterology, colorectal cancer prevention, dermatology and women’s health.

REFERENCE: 1. IQVIA. National Prescription Audit Report. March 2021.